• We are catalysts for innovation, commercialising next-generation technologies developed by

    The University of Manchester’s world-class research base





    • £360m+ invested by venture funders

    • 40+ spin-out companies created

    • 7,500+ licences and IP partnerships concluded

    • 4,000+ invention disclosures received

    • £115m+ IP and R&D revenue generated for the University







  • We are catalysts for innovation, commercialising next-generation technologies developed by The University of Manchester’s world-class research base





    • £300m+ invested by venture funders since 2004

    • 40+ spin-out companies created

    • 4,800+



      licences and IP partnerships concluded

    • 3,700+ invention disclosures received

    • 1,300+ jobs generated across various industry sectors

    • £105m+ IP and R&D revenue generated for the University


Myconostica Ltd Closes Oversubscribed $7.7 Million Round and Establishes US Headquarters in Charleston

Financing to bring advanced medical diagnostics for
life-threatening infections to market and establish US presence.

April 2008, Manchester UK and Charleston, SC- Myconostica Ltd, a Manchester UK-based medical diagnostic company specializing in rapid and highly specific tests for life-threatening fungal infections, today announces that it has closed an $7.7 million (£3.9M) oversubscribed round of financing from a number of leading international private equity investors. The new funds will be used to launch the company’s first two products and establish new US headquarters in Charleston, SC.

Over 10 million people are at risk of invasive fungal infections in Europe and
North America each year. This number is increasing rapidly with the large
growth in patients whose treatments involves transplants and/or the use of
immuno-suppressive drugs, leaving them susceptible to fungal infection. Current
diagnostic methods are too slow and non-specific for optimal patient care.
Myconostica which was formed in 2006 as a spin out from the University of
Manchester, is developing and commercializing tests based on highly specific genetic “signatures” unique to each disease and allow faster and much more
precise diagnosis. These “molecular diagnostics” are simple and can detect
multiple fungi in a single process.

The completion of the series C financing was led by Nexus Medical Partners (Boston and Charleston) and also featured Innoven Partenaires (France), the principal international investors joining existing investor Amphion Innovations (AIM: AMP-L) in the round. This second close brings the total raised, in the current Series C financing, to approximately $8.6 Million(£4.4 M).

The capital raised in this round of financing will support the launch of
Myconostica’s first two products. The first product is the world’s first real-time molecular diagnostic simultaneously testing for both Aspergillus and Pneumocystis. The second product is a fungal DNA extraction system. The diagnostic product, announced at the Trends in Medical Mycology meeting in Turin in October 2007, is CE marked, which enables sales in Europe and several other territories. The investment will also allow development of further diagnostic tests in the FXG series targeting other critical fungal infections. Myconostica will be applying to the FDA for regulatory approval to launch the products in the US market.

Following the latest fund raising, Myconostica are also pleased to announce the opening of its US headquarters in Charleston, South Carolina. The new office, Myconostica’s first outside of the UK, will be the focus for North American operations and was chosen after careful review of alternative locations. South Carolina has a growing cluster of medtech and biotech industry.

Gregory Zaic, Nexus’s senior partner in charge of Nexus’s Charleston office, introduced the company to key clinicians at MUSC, thanks to suggestions by MUSC’s president, Dr. Ray Greenberg. The company is establishing clinical cooperation with members of the MUSC faculty. The location of Myconostica’s US office is being facilitated by the City Of Charleston’s Life Science Initiative (of which Nexus is a supporter). Nexus is one of the four venture capital firms to receive state sponsored funding under the South Carolina Venture Capital Investment Act.

Myconostica welcome:

Dr. Edwin Snape to their Board. Dr. Snape is co-founder and head of the healthcare practice at Nexus Medical Partners (Boston and Charleston) and has been involved in venture investing for the past 30 years. He brings further valuable commercial and diagnostics sector expertise to the company.
Spencer Kerry as Chief Financial Officer. Mr. Kerry, a Cambridge law graduate who qualified as an accountant with Deloitte and Touche, has over ten years experience in various senior corporate financial roles most recently as Business Controller at Edinburgh based biotech company Ardana PLC.

Dr. Snape indicated “I am pleased to accept the Board position at Myconostica. The company represents an excellent example of Nexus bringing into South Carolina an exciting, knowledge-based company. In addition, the $2 million invested by Nexus through its fund, was supplemented by three times that amount of capital via coinvestors.”

Professor David Denning, founder of Myconostica, and a world leading authority on fungal disease at the University Hospital of South Manchester, said, “I am very pleased with the exceptional level and quality of international response to this financing opportunity as it allows us to continue the exceptionally rapid
progress in the development of our company and our current and future products. The medical need for these products is clear and growing.”

Jerel Whittingham, Chief Executive Officer of Myconostica commented, “At such a difficult time in financial markets, Myconostica’s success in this oversubscribed fund-raising is a tremendous endorsement of our commercial prospects and we will only succeed commercially by making a real difference medically. “

For further information please contact:

Myconostica Ltd
Jerel Whittingham, CEO, (Manchester):
+44 (0)7779 095604 / +44 (0)161 998 7239
Dr. John Thornback, Chief Operations Officer (currently in US):
Mobile/Cell +44 (0) 7968 726573

About Myconostica Ltd.
Myconostica is a medical diagnostics company, spun out of The University of
Manchester in 2006 specializing in molecular diagnostic tests for life-threatening
invasive fungal infections. Myconostica has its Head Office and laboratories in
South Manchester, and has strong links to the University Hospital South
Manchester and the Regional Mycology Laboratory, Manchester. Founded by
David Denning, Professor of Medicine and Medical Mycology, Myconostica has a
strong pipeline of products, the first of which will be launched in 2008.
On the web: www.myconostica.co.uk
Myconostica is a partner company of Amphion Innovations.

Spin-out venture fund achieves first close

MTI and The University of Manchester today announce the first close of Europe’s largest institutional fund to have a single university focus ndash; the UMIP Premier Fund (“the Fund”).

With funding from a broad range of UK and European institutional and supranational investors, including EIF (European Investment Fund), NESTA (National Endowment for Science, Technology and the Arts), Co-operative Insurance Society and others, the Fund has initial backing of €42 million (£32 million). The fund manager, MTI, believes that it is likely the Fund will eventually close at €65 million (£50 million).

The Fund will make most of its initial investments in the £250,000 – £750,000 range, but with the intention and the capacity to continue investing up to an average of £2m – £3m. Once it is fully invested, the Fund is expected to comprise a portfolio of approximately 20 investments.

The University of Manchester & UMIP
The University of Manchester is the UK’s largest university, with over 30,000 students and 4,500 academic and research staff, and the alma mater of 20 Nobel Prize winners. The University has a successful spin-out track-record, and the early stage commercialisation of the University’s intellectual property through successful spin-outs will continue to be managed by The University of Manchester Intellectual Property Ltd (“UMIP”).

Companies which have emerged from the University have attracted over £150m of funding over the last 5 years and include successes such as Transitive, and Renovo – a wound treatment company listed on the London Stock Exchange and valued at approx. £300m.

The UMIP Premier Fund will have preferred access to all investment opportunities generated by technology research at The University of Manchester, which has an abundance of 5-star research departments, and boasts some of the finest technology investment opportunities in the UK. The Fund will focus on investing in young technology companies, and will have both the ability and capacity to support their growth through follow-on investment.

Professor Alan Gilbert, President and Vice-Chancellor of The University of Manchester said: “This is a ground-breaking initiative establishing a hugely creative vehicle for providing academics with access to the capital to develop the world-leading research, for which the UK is renowned, into world-beating companies.”

MTI
UMIP has teamed up with the UK’s leading technology investment manager, MTI, in order to exploit the rich seam of latent opportunity within The University of Manchester and to turn it into commercial success.

The UMIP Premier Fund will draw on MTI’s experience of investing in technology companies and developing their operational and marketing excellence. MTI’s experience in injecting new skills, contacts and strategies will drive growth and success in these investment areas.
MTI has more than two decades of investment management experience, and over that period has managed four venture funds dedicated to technology investments. MTI is in the process of appointing a dedicated, professional technology fund manager for UMIP to be based in Manchester.

Ernie Richardson, CEO at MTI, said: “We have seen evidence of some incredible ideas within the research departments of The University of Manchester. This Fund will enable those researchers to gain access to the finance and business skills to turn their ideas into real businesses, and generate substantial value. What could be more exciting? The support of our investors like EIF, has enabled us to create the biggest such fund in Europe.”

A launch event will be held in London during May.

For further information on The UMIP Premier Fund please visit www.theupf.com

Contact information:
MTI
Ernie Richardson, Managing Partner + 44 (0) 1923 250 244
Robin Hepburn, Media contact for MTI + 44 (0) 20 7796 9999

The University of Manchester/UMIP
Professor Rod Coombs, VP for Innovation and Economic
Development, The University of Manchester + 44 (0) 161 275 8860
Clive Rowland, CEO, UMIP + 44 (0) 161 603 7751
Allan Prits, Marketing Manager, UMIP + 44 (0) 161 306 8532

Top Marks and a £250K Investment for Manchester Invention

An innovative piece of software that takes pressure off teachers by marking exam papers quicker and more efficiently than humans has secured a quarter-of-a-million pound funding.

University of Manchester spin-out company, Assessment21, has become the first to create a tool that can not only mark multi-choice answers but also open-ended responses. Until now many have tried and failed to create software that can do this. The product – ABC (Assess By Computer) – is seen as a major breakthrough for the education sector. UMIP (The University of Manchester’s IP commercialisation company) helped develop a management team and worked with the company to raise external funding.

South Yorkshire Investment Fund and three business angels have invested £250,000 to take the software to market ndash; specifically aiming at the higher education and professional associations markets.

The main advantages are that, compared to manually marking papers, the ABC software is quicker, more efficient and more consistent but still leaves the final judgments to humans. It allows students to remain anonymous to the marker, takes away the difficulties of reading illegible handwriting and the physical problems of handling bulky paper.

Assessment21 director Gerard Lennox said: “The product is a classic example of how to take cutting-edge research, apply commercial experience and a relatively small investment to create a viable company that satisfies a clearly identified market need.”

The technology handles all aspects of the assessment process, including setting exam questions, administration and marking. It has been used for four years at The University of Manchester on a wide variety of assessments including final year exams and course work.

Heather White, Senior Business Manager at UMIP, said “It’s very pleasing to see a truly innovative product which has already proved its worth in the University being taken to external markets by Assessment21, as the benefits of the software are very significant in terms of time savings and security.”

For information about Assessment21 contact Gerard Lennox 07973 218271
www.assessment21.com

Manchester Innovators make Breakthrough for Women

A piece of software developed in Manchester that can detect osteoporosis by automatically reading routine dental X-rays has secured a deal that could see it help millions of women world-wide.

The technology, Osteodent, which is being commercialised by UMIP (The University of Manchester’s IP commercialisation company), has secured a deal with Swedish company Crebone AB for the rights to sell the software until 2010.

The software is designed to increase the detection rates of osteoporosis, which can be treated effectively if identified early. Currently, most women with osteoporosis don’t realise they have the condition until late in the disease when they suffer a bone fracture of the spine, hip or wrist. In the UK alone, there are an estimated 3.5million suitable dental X-ray examinations carried out each year.

The University of Manchester received a €1.4m EU grant in 2003 to conduct a study of 670 women’s X-rays in the UK, Sweden, Belgium and Greece. The results of the study, which have recently been published, show that Osteodent is the most accurate method for identifying individuals with osteoporosis using dental X-rays and clinical markers.

Since the results of the European study were announced there has been a high level of interest in the product. German dental company, KaVo, is currently undertaking an audit project using Osteodent software that is aimed at improving dentists diagnostic abilities.

Osteodent has been developed by The University of Manchester’s Dr Hugh Devlin, Dr Jim Graham, Dr Danny Allen and Professor Keith Horner. The initial idea was conceived 18 years ago. UMIP now has two patents on the software, one for North America and one for the rest of the world. Osteodent won the BioNow Healthcare Project of the Year 2007, sponsored by TrusTECH.

Professor of Oral and Maxillofacial Imaging, Keith Horner said: “Currently it tends to be only ‘the worried well’ or those with well-informed GPs whose osteoporosis risk is properly assessed. Osteodent will open up the opportunity of being tested to millions of women who attend a dentist and would otherwise not be tested.

“We’re very excited about this product because we know it has enormous potential. As Osteodent works as part of a routine dental appointment it could have substantial benefits for our NHS financially. In countries with private healthcare systems, Osteodent could also be very lucrative to dentists.”

Professor Stuart C. White, Chair of Oral and Maxillofacial Radiology at UCLA School of Dentistry in the USA commented: “Osteoporosis affects millions of aging men and women worldwide. Since a large fraction of adults seek dental care annually, Osteodent offers the opportunity to screen many individuals for early signs of osteoporosis. This is a truly exciting development.”

For more information contact Dr Stephen France at UMIP on 0161 606 7249.

Illuminating Research – A bright future ahead as Nanoco sign a distribution agreement with Sigma-Aldrich

Nanoco Technologies Ltd, Manchester, UK 18 January 2008

Nanoco Technologies and Sigma-Aldrich are looking at a bright future together with the signing of a distribution agreement and launch of a new range of products based on Nanoco´s leading edge quantum dots.

The first materials available through this collaboration form the new Lumidotâ„¢ range of seven core-shell fluorescent quantum dots . Quantum dots (QDs) are nm-sized semiconductor nanoparticles that emit bright, near-monochromatic light (luminesce) under light or electrical stimulation. Emission color can be tuned by choosing nanocrystal size, making QDs ideal luminophors for cutting-edge applications including ultra-thin displays, solid-state lighting, anti-counterfeit protection, and next-generation solar cells. Nanoco developed unique manufacturing methods for making multi-gram quantities of QDs reproducibly and with precise control of size, structure, and luminescence characteristics. The new core-shell LumidotsTM distributed by Sigma-Aldrich have luminescence colors spanning the entire visible spectrum, in addition to good stability and batch-to-batch reproducibility, essential for research into high-technology applications.

The relationship makes the most of the core skills of both companies. Nanoco is unique in the Nanomaterials market as a company that manufactures large quantities of quantum dots. Sigma-Aldrich provide an excellent distribution channel as they are uniquely positioned to deliver smaller quantities of chemicals to commercial, academic and government labs around the world.

“This partnership is great for both companies and for global research”, said Michael Edelman, CEO of Nanoco Technologies, “It brings Nanoco´s manufacturing expertise together with the excellent distribution network operated by Sigma-Aldrich. We are excited to be working with them to extend the range of nanomaterials available to the worldwide research market. We plan to expand this collaboration by offering new ranges of quantum dots later in 2008 and beyond.”

“The new LumidotsTM are an important addition to our line of nanomaterials products, providing researchers around the world reliable access to high-quality quantum dot nanocrystals. Using these materials, scientists and engineers can focus on developing applications that take advantage of the unique properties of quantum dots. This fits with the main goal of Aldrich Materials Science ndash; we focus on materials so that our customers can focus on results,” said Dr. Ilya Koltover, Product Manager, Aldrich Materials Science.
Sigma-Aldrich will distribute research quantities (less than 1 g) of the quantum dots and the Lumidotâ„¢ range will be supplied as convenient 2 mL and 10 mL solutions in toluene, available to order from the Sigma-Aldrich website.

Nanoco will continue to offer larger quantities of quantum dots to partners who move beyond research to development of commercial QD applications.

About Nanoco (www.nanocotechnologies.com)
Nanoco is a nano-material science company that holds patents related to industrial-scale production of Quantum Dots. Quantum Dots are Fluorescent semi-conducting nanocrystals that can be used in a range of applications from biological imaging to next generation solar cells and displays. The University of Manchester spinout was founded in 2001 and works in partnership with technology driven corporations to bring quantum dot based applications to the market around the world.

CONTACT US